Short answer
MIMEDX GROUP, INC. (MDXG) filed its Q3 2025 10-Q quarterly report on Oct 29, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $114M (up 35.3% year over year) with net income of $17M.
Q3 2025 key financials · XBRL
- Revenue
- $114M
- +35.3% YoY · +15.3% QoQ
- Net income
- $17M
- +106.9% YoY · +74.2% QoQ
- Operating margin
- 19.5%
- Gross margin
- 83.5%
- EPS (diluted)
- $0.11
- +120.0% YoY · +83.3% QoQ
Source: XBRL data from the MIMEDX GROUP, INC. (MDXG) Q3 2025 10-Q on SEC EDGAR. USD.
MIMEDX GROUP, INC. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Q3 revenue $113.7M, up 35.3% YoY from $84.1M
- Gross margin 83.5% vs 81.8% YoY; net income $16.7M with 15% margin
- Best segment Wound: $77.1M, up 40.0%; Surgical $36.6M, up 26.3%
- Cash $142.1M, up $53M YoY and $23M sequentially; nine-month operating cash flow $49.0M
- CMS proposals target $125.38 per square centimeter reimbursement from January 1, 2026, creating potential industry headwinds
Risk Factors
- No material changes to risk factors from the 2024 Form 10-K
- No new Rule 10b5-1 or non-Rule 10b5-1 trading arrangements during the quarter
- No unregistered equity sales reported during the quarter
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other MIMEDX GROUP, INC. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.